Ficlatuzumab joins Beat AML trial: is AVEO’s c-Met inhibitor ready for broader testing?

AVEO begins new trial of ficlatuzumab in front-line AML with Beat AML. Find out what this signals for older patients and c-Met inhibitor development.

AVEO begins new trial of ficlatuzumab in front-line AML with Beat AML. Find out what this signals for older patients and c-Met inhibitor development.